WENDER JOSEPH H

SEC source: 0000874015-25-000288 · edgardoc.xml · nonDerivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · by Trust

Disclosed balance after: 36,035

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 26, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.12 to $81.435 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-25-000288 · edgardoc.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · by Trust

Disclosed balance after: 43,464

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 26, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.11 to $81.11 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-25-000282 · edgardoc.xml · derivative · entry 3

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,000 shares

Expires 2026-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-25-000282 · edgardoc.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2026.

SEC source: 0000874015-25-000272 · edgardoc.xml · nonDerivative · entry 4

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · by Trust

Disclosed balance after: 64,035

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 26, 2024.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.41 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) on this Form 4.

SEC source: 0000874015-25-000272 · edgardoc.xml · nonDerivative · entry 3

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · by Trust

Disclosed balance after: 75,235

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 26, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.6750 to $74.28 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.

SEC source: 0000874015-25-000272 · edgardoc.xml · nonDerivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · by Trust

Disclosed balance after: 81,210

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 26, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.63 to $73.63 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-25-000272 · edgardoc.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · by Trust

Disclosed balance after: 89,551

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 26, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.62 to $72.62 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-25-000246 · edgardoc.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · by Trust

Disclosed balance after: 92,035

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 26, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.02 to $65.86 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-25-000223 · edgardoc.xml · nonDerivative · entry 3

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · by Trust

Disclosed balance after: 108,835

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 16, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.53 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.

SEC source: 0000874015-25-000216 · edgardoc.xml · nonDerivative · entry 3

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · by Trust

Disclosed balance after: 108,835

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 16, 2024.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.53 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.

SEC source: 0000874015-25-000223 · edgardoc.xml · nonDerivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · by Trust

Disclosed balance after: 120,035

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 16, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.500 to $57.575 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-25-000223 · edgardoc.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · by Trust

Disclosed balance after: 125,635

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 16, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.000 to $55.180 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-25-000216 · edgardoc.xml · nonDerivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · by Trust

Disclosed balance after: 120,035

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 16, 2024.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.500 to $57.575 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

SEC source: 0000874015-25-000216 · edgardoc.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Plan reported

Ownership: Indirect · by Trust

Disclosed balance after: 125,635

F1 · shares: Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on December 16, 2024.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.000 to $55.180 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

SEC source: 0000874015-25-000160 · edgardoc.xml · derivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,141

Underlying: Common Stock · 4,079 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-25-000160 · edgardoc.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 136,835

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-25-000143 · edgardoc.xml · derivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,299

Underlying: Common Stock · 5,220 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F4 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

F4 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2025.

SEC source: 0000874015-25-000143 · edgardoc.xml · derivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,518

Underlying: Common Stock · 11,518 shares

Expires 2035-06-30

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

F2 · derivative.expiration_date: Grant on July 1, 2025 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2025.

SEC source: 0001579877-25-000077 · wk-form4_1749160826.xml · derivative · entry 3

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted share units are settled by delivery of a corresponding number of shares of common stock of OUTFRONT Media Inc. (the "Company") upon vesting.

F4 · derivative.exercise_date: These restricted share units vest in full on June 3, 2025.

F4 · derivative.expiration_date: These restricted share units vest in full on June 3, 2025.

SEC source: 0001579877-25-000077 · wk-form4_1749160826.xml · nonDerivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,996

F3 · kind: Includes shares acquired due to the settlement of dividend equivalents into shares of the Company's common stock at vesting.

F3 · price: Includes shares acquired due to the settlement of dividend equivalents into shares of the Company's common stock at vesting.

SEC source: 0001579877-25-000077 · wk-form4_1749160826.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,225

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted share units are settled by delivery of a corresponding number of shares of common stock of OUTFRONT Media Inc. (the "Company") upon vesting.

F2 · balance_after: Total shares of the Company's common stock reflect the impact of the common stock portion of the Company's special dividend paid on December 31, 2024, and the reverse stock split on the Company's common stock effectuated on January 17, 2025.

SEC source: 0000874015-24-000183 · edgardoc.xml · derivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,079

Underlying: Common Stock · 4,677 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-24-000183 · edgardoc.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 132,756

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-24-000166 · edgardoc.xml · derivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,756

Underlying: Common Stock · 4,079 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F4 · derivative.exercise_date: Grant on July 1, 2024 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2024.

F4 · derivative.expiration_date: Grant on July 1, 2024 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2024.

SEC source: 0000874015-24-000166 · edgardoc.xml · derivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,111

Underlying: Common Stock · 10,111 shares

Expires 2034-06-30

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2024 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024.

F2 · derivative.expiration_date: Grant on July 1, 2024 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2024.

SEC source: 0001579877-24-000078 · wk-form4_1718051851.xml · derivative · entry 3

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 9,863 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted share units are settled by delivery of a corresponding number of shares of common stock of OUTFRONT Media Inc. (the "Company") upon vesting.

F3 · derivative.exercise_date: These restricted share units vest in full on June 6, 2024.

F3 · derivative.expiration_date: These restricted share units vest in full on June 6, 2024.

SEC source: 0001579877-24-000078 · wk-form4_1718051851.xml · nonDerivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 59,356

F2 · kind: Includes shares acquired due to the settlement of dividend equivalents into shares of the Company's common stock at vesting.

F2 · price: Includes shares acquired due to the settlement of dividend equivalents into shares of the Company's common stock at vesting.

SEC source: 0001579877-24-000078 · wk-form4_1718051851.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,732

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted share units are settled by delivery of a corresponding number of shares of common stock of OUTFRONT Media Inc. (the "Company") upon vesting.

SEC source: 0001579877-24-000061 · wk-form4_1717534290.xml · derivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,125

Underlying: Common Stock · 10,125 shares

Expires not disclosed

F1 · derivative.exercise_price: The restricted share units are settled by delivery of a corresponding number of shares of common stock of OUTFRONT Media Inc. upon vesting.

F2 · derivative.exercise_date: These restricted share units vest in full on June 3, 2025.

F2 · derivative.expiration_date: These restricted share units vest in full on June 3, 2025.

SEC source: 0000874015-24-000146 · edgardoc.xml · derivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,000 shares

Expires 2024-06-30

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000874015-24-000146 · edgardoc.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 128,079

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquired as a result of exercising a stock option that was scheduled to expire on 6/30/2024.

SEC source: 0000874015-23-000179 · edgardoc.xml · derivative · entry 4

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,677

Underlying: Common Stock · 5,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F4 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-23-000179 · edgardoc.xml · derivative · entry 3

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,010

Underlying: Common Stock · 1,777 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

F3 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments. Upon vesting, the restricted stock units will be paid out in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-23-000179 · edgardoc.xml · nonDerivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 112,079

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-23-000179 · edgardoc.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 106,746

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-23-000161 · edgardoc.xml · derivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,787

Underlying: Common Stock · 4,677 shares

Expires not disclosed

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2023 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F4 · derivative.exercise_date: Grant on July 3, 2023 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 3, 2023.

F4 · derivative.expiration_date: Grant on July 3, 2023 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 3, 2023.

SEC source: 0000874015-23-000161 · edgardoc.xml · derivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,321

Underlying: Common Stock · 10,321 shares

Expires 2033-07-02

F1 · shares: Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2023 totals no more than $450,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718.

F2 · derivative.exercise_date: Grant on July 3, 2023 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 3, 2023.

F2 · derivative.expiration_date: Grant on July 3, 2023 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 3, 2023.

SEC source: 0001579877-23-000070 · wk-form4_1686267907.xml · derivative · entry 4

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,290 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted share units are settled by delivery of a corresponding number of shares of common stock of OUTFRONT Media Inc. (the "Company") upon vesting.

F4 · derivative.exercise_date: These restricted share units vest in full on June 7, 2023.

F4 · derivative.expiration_date: These restricted share units vest in full on June 7, 2023.

SEC source: 0001579877-23-000070 · wk-form4_1686267907.xml · nonDerivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,869

F2 · kind: Includes shares acquired due to the settlement of dividend equivalents into shares of the Company's common stock at vesting.

F2 · price: Includes shares acquired due to the settlement of dividend equivalents into shares of the Company's common stock at vesting.

SEC source: 0001579877-23-000070 · wk-form4_1686267907.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,293

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The restricted share units are settled by delivery of a corresponding number of shares of common stock of OUTFRONT Media Inc. (the "Company") upon vesting.

SEC source: 0001579877-23-000070 · wk-form4_1686267907.xml · derivative · entry 3

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,863

Underlying: Common Stock · 9,863 shares

Expires not disclosed

F1 · derivative.exercise_price: The restricted share units are settled by delivery of a corresponding number of shares of common stock of OUTFRONT Media Inc. (the "Company") upon vesting.

F3 · derivative.exercise_date: These restricted share units vest in full on June 6, 2024.

F3 · derivative.expiration_date: These restricted share units vest in full on June 6, 2024.

SEC source: 0000874015-22-000144 · edgardoc.xml · derivative · entry 4

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,110

Underlying: Common Stock · 2,665 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F5 · derivative.exercise_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F5 · derivative.expiration_date: Restricted Stock Units vest in four equal annual installments and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-22-000144 · edgardoc.xml · derivative · entry 3

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,775

Underlying: Common Stock · 5,333 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F4 · derivative.exercise_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

F4 · derivative.expiration_date: Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and are delivered to the reporting person on the July 15th following the vesting date. Upon vesting, the Restricted Stock Units will be paid in whole shares of Ionis common stock or cash as may be determined by the Company.

SEC source: 0000874015-22-000144 · edgardoc.xml · nonDerivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 104,969

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · kind: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

F2 · shares: Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.

SEC source: 0000874015-22-000144 · edgardoc.xml · nonDerivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · by Trust

Disclosed balance after: 102,304

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

F1 · shares: Acquired pursuant to vesting and release of shares in accordance with a Restricted Stock Unit award.

SEC source: 0000874015-22-000126 · edgardoc.xml · derivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,108

Underlying: Common Stock · 5,333 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

F3 · derivative.exercise_date: Grant on July 1, 2022 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2022.

F3 · derivative.expiration_date: Grant on July 1, 2022 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 1, 2022.

SEC source: 0000874015-22-000126 · edgardoc.xml · derivative · entry 1

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,000

Underlying: Common Stock · 12,000 shares

Expires 2032-06-30

F1 · derivative.exercise_date: Grant on July 1, 2022 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2022.

F1 · derivative.expiration_date: Grant on July 1, 2022 to reporting person of stock options under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. 100% of the shares subject to the option vest and become exercisable on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier. The option is exercisable to 0 shares on July 1, 2022.

SEC source: 0001579877-22-000063 · wf-form4_165480602357038.xml · derivative · entry 4

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,907 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The restricted share units are settled by delivery of a corresponding number of shares of common stock of OUTFRONT Media Inc. (the "Company") upon vesting.

F4 · derivative.exercise_date: These restricted share units vest in full on June 8, 2022.

F4 · derivative.expiration_date: These restricted share units vest in full on June 8, 2022.

SEC source: 0001579877-22-000063 · wf-form4_165480602357038.xml · nonDerivative · entry 2

WENDER JOSEPH H · CIK 0001073384 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,003

F2 · kind: Includes shares acquired due to the settlement of dividend equivalents into shares of the Company's common stock at vesting.

F2 · price: Includes shares acquired due to the settlement of dividend equivalents into shares of the Company's common stock at vesting.